‌

US Patent 11472842 Analogues of hepcidin mimetics with improved in vivo half lives

Patent 11472842 was granted and assigned to Protagonist Therapeutics on October, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Protagonist Therapeutics

0

Current Assignee

Protagonist Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Mark Leslie Smythe0

Ashok Bhandari0

Brian Troy Frederick0

Gregory Thomas Bourne0

Date of Patent

October 18, 2022

0

Patent Application Number

170613360

Date Filed

October 1, 2020

0

Patent Citations

US Patent 10278957 Opioid agonist peptides and uses thereof

0

US Patent 10301371 Cyclic monomer and dimer peptides having integrin antagonist activity

US Patent 10407468 Methods for synthesizing α4β7 peptide antagonists

US Patent 10442846 Hepcidin analogues and uses thereof

US Patent 10501515 Hepcidin analogues and uses thereof

US Patent 10626146 α4β7 thioether peptide dimer antagonists

0

US Patent 10729676 Opioid agonist peptides and uses thereof

0

US Patent 10787490 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

0

...

Patent Citations Received

US Patent 11753443 Conjugated hepcidin mimetics

Patent Primary Examiner

0

The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11472842 Analogues of hepcidin mimetics with improved in vivo half lives

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.